Prudential Financial Inc. Has $1.96 Million Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Prudential Financial Inc. increased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 173.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,968 shares of the medical research company's stock after buying an additional 3,784 shares during the quarter. Prudential Financial Inc.'s holdings in Bio-Rad Laboratories were worth $1,961,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BIO. Venturi Wealth Management LLC raised its position in Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after acquiring an additional 87 shares in the last quarter. Picton Mahoney Asset Management grew its stake in shares of Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after purchasing an additional 35 shares during the last quarter. Asset Planning Inc bought a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth approximately $33,000. UMB Bank n.a. lifted its stake in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. bought a new stake in Bio-Rad Laboratories during the fourth quarter worth approximately $38,000. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Up 12.6 %

Shares of BIO traded up $27.71 during mid-day trading on Wednesday, reaching $248.22. The company's stock had a trading volume of 568,099 shares, compared to its average volume of 316,969. Bio-Rad Laboratories, Inc. has a 1 year low of $215.38 and a 1 year high of $387.99. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The company has a market cap of $6.95 billion, a price-to-earnings ratio of -3.82 and a beta of 1.12. The business has a fifty day moving average of $269.27 and a 200 day moving average of $315.95.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. StockNews.com cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Wells Fargo & Company reduced their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a report on Wednesday, February 12th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.